- ASSISTANT CLINICAL PROFESSOR | Psychiatry
- Hospital Affiliation
- The Mount Sinai Hospital
Child & Adolescent Psychiatry
Psychiatry, American Board of Psychiatry and Neurology
MD, Rutgers Robert Wood Johnson Medical School
BA, University of Pennsylvania
Mount Sinai Hospital
Fellowship, Child and Adolescent Psychiatry
Mount Sinai Hospital
Carpenter DM, Tang CY, Friedman JI, Hof PR, Stewart DG, Buchsbaum MS, Harvey PD, Gorman JG, Davis KL. Temporal characteristics of tract-specific anisotropy abnormalities in schizophrenia. Neuroreport 2008 Sep 17; 19(14): 1369-1372.
Friedman JI, Tang C, Carpenter D, Buchsbaum M, Schmeidler J, Flanagan L, Golembo S, Kanellopoulou I, Ng J, Hof PR, Harvey PD, Tsopelas ND, Stewart D, Davis KL. Diffusion tensor imaging findings in first-episode and chronic schizophrenia patients. American Journal of Psychiatry 2008 Aug; 165(8): 1024-1032.
Stewart DG, Davis KL. The Lobotomist: Images in Psychiatry. American Journal of Psychiatry 2008 Apr; 165: 457-458.
Stewart DG, Davis KL. The Neuropathology of Schizophrenia. In: Mueser K, Jeste D, editors. Clinical Textbook of Schizophrenia (2008). The Guilford Press;.
Buchsbaum MS, Friedman JI, Buchsbaum BR, Chu KW, Hazlett E, Newmark R, Schneiderman J, Torosjan Y, Tang C, Hof P, Stewart DG, Davis KL, Gorman J. Diffusion tensor imaging in schizophrenia. Biological Psychiatry 2006 Dec 1; 60(11): 1181-1187.
Stewart DG, Davis KL. Possible contributions of myelin and oligodendrocyte dysfunction to schizophrenia. International Review of Neurobiology 2004; 59: 381-424.
Kolevzon A, Stewart D, editors. Psychiatry Pearls (2004). Hanley & Belfus;.
Friedman JI, Stewart DG, Gorman JM. Potential noradrenergic targets for cognitive enhancement in schizophrenia. CNS Spectrums 2004 May; 9(5): 350-355.
Davis K, Stewart D, Friedman J, Buschbaum M, Harvey P, Hof P, Buxbaum J, Haroutunian V. White Matter Changes in Schizophrenia: Evidence for Myelin-Related Dysfunction. Archives of General Psychiatry 2003 May; 60(5): 443-456.
Saks N, Zingale C, Stewart D. How to Excel in Medical School, First Edition (1998). J & S Publishers;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Stewart is not currently required to report Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.